These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33043477)

  • 1. The ethics of grandfather clauses in healthcare resource allocation.
    Wester G; Gibson Rand LZ; Lu C; Sheehan M
    Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Cowles E; Marsden G; Cole A; Devlin N
    Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ethics of attaching research conditions to access to new health technologies.
    Holland S; Hope T
    J Med Ethics; 2012 Jun; 38(6):366-71. PubMed ID: 22345547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICE guidance in the Scottish context.
    Kohli H; Tannahill A
    Scott Med J; 2009 Feb; 54(1):35-8. PubMed ID: 19291935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.